Light-activated AU-011 has the potential to be the first targeted therapy ever developed for the primary treatment of ocular melanoma, the most common primary cancer of the eye, said Amy C. Schefler, MD, with Retina Consultants of Houston.
People diagnosed with ocular melanoma confront "an array of poor treatment options, which often result in severe vision loss, removal of the eye, and in about half of all cases, metastasis to the liver, where the disease is nearly always fatal," according to Aura Biosciences, which developed this light-activated technology.
AU-011 is a novel recombinant papillomavirus-like particle (VLP) drug conjugate, first-in-class targeted therapy; the FDA has already granted Fast Track Designation and orphan drug designation, recognizing that there are no FDA-approved therapies and that the disease is serious and life-threatening, Dr. Schefler said.
The mechanism of action of AU-011 is targeted acute tumor cellular necrosis upon light activation.
Dr. Schefler is an investigator for Aura Biosciences and receives grants from Aura Biosciences.